Animal Pharm's Top 20 is recognised throughout the animal health and nutrition industry as a key source of information and analysis on the 20 largest companies in the sector. Invest in this report to keep informed of the performance of your potential competitors, collaborators or customers.

Key Findings:
- Global sales of animal health and nutrition products totalled almost US$21.7 billion in 2005. That figure was around 7% higher than the year-earlier total of US$20.3 billion.
- Sales of veterinary pharmaceuticals and biologicals for use in small animals alone are now worth almost US$6 billion, a figure equivalent to more than 27% of the entire market.
- The 13% increase in revenues reported by Pfizer Animal Health in 2005 saw the company consolidate its position at the head of the global sales league, with a gap of more than US$200 million between it and second-placed Merial.
- Merial appears set to leapfrog Pfizer in 2006, regaining the leadership position it held prior to Pfizer's acquisition of Pharmacia Corp in 2003.
- The acquisition of Adisseo by the China National Chemical Corp (CNCC), announced late in 2005 and completed in 2006, is among the most significant M&A developments reported recently in the industry.
- Despite SPAH's recent problems in the US market, most recent results indicate that the worst may finally be behind the company, with US sales up sharply on year-earlier figures in the first half of 2006.
- Merial's Frontline sales fell back by 11% on year-earlier figures in the third quarter of 2005. That was followed by a 31% gain in the final quarter, however, and further strong growth through the first half of 2006.